Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 7/20 | 0.45 |
| ▸ | MAP2K2 | P36507 | 3/20 | 0.45 |
| ▸ | SMC2 | O95347 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.45 |
| ▸ | SMC1A | Q14683 | 1/20 | 0.45 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.45 |
| ▸ | Q6ZSR9 | Q6ZSR9 | 1/20 | 0.45 |
| ▸ | BMP2K | Q9NSY1 | 1/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CTDSP1 | Q9GZU7 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | RAB9A | P51151 | 2/20 | 0.35 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | SORT1 | Q99523 | 2/20 | 0.35 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18272624 | 0.91 | MAP2K1 (0.49) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL6016670 | 0.89 | MAP2K1 (0.48) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL4414265 | 0.89 | MAP2K1 (0.53) | MAP2K1MAP2K2ACLYNPC1RAB9A | |
| SCHEMBL2023615 | 0.89 | MAP2K1 (0.49) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL1037390 | 0.89 | MAP2K1 (0.47) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL1041886 | 0.89 | MAP2K1 (0.47) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL30886595 | 0.89 | MAP2K1 (0.47) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL27619742 | 0.89 | MAP2K1 (0.42) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL7541506 | 0.87 | MAP2K1 (0.60) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 | |
| SCHEMBL6016781 | 0.87 | MAP2K1 (0.43) | MAP2K1MAP2K2SMC2EGFRCSNK2A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | claimed |
| CN-1652776-A | N3 alkylated benzimidazole derivatives as MEK inhibitors | ARRAY BIOPHARMA INC (US) | 2005-08-10 | — | — | CN | claimed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | claimed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | claimed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | claimed |
| CN-116617401-A | Compositions for treating cancer using PD-1 axis binding antagonists and MEK inhibitors | 豪夫迈·罗氏有限公司 | 2023-08-22 | — | — | CN | disclosed |
| CN-116376826-A | Compositions and methods for immune cell modulation in adoptive immunotherapy | 菲特治疗公司 | 2023-07-04 | — | — | CN | disclosed |
| CN-108473959-B | Compositions and methods for immune cell modulation in adoptive immunotherapy | 菲特治疗公司 | 2023-04-21 | — | — | CN | disclosed |
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | GENENTECH, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-3563870-A1 | METHODS OF TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2019-11-06 | — | — | EP | disclosed |
| EP-3169361-B1 | COMPOSITIONS FOR TREATING CANCER USING PD-1 AXIS BINDING ANTAGONISTS AND MEK INHIBITORS | HOFFMANN LA ROCHE (CH) | 2019-06-19 | — | — | EP | disclosed |
| EP-1663210-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2006-06-07 | — | — | EP | disclosed |
| EP-1482932-A4 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC (US) | 2006-04-05 | — | — | EP | disclosed |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | ALEXION PHARMA INTERNATIONAL OPERATIONS LIMITED (IE) | 2005-06-30 | — | — | US | disclosed |
| WO-2005023251-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2005-03-17 | — | — | WO | disclosed |
| EP-1482932-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | Array Biopharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040116710-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2004-06-17 | — | — | US | disclosed |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
| WO-2003077914-A1 | N3 ALKYLATED BENZIMIDAZOLE DERIVATIVES AS MEK INHIBITORS | ARRAY BIOPHARMA, INC (US) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10946093-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885MAP2K2 17/4885SMC2 4284/4885 |
| US-20030232869-A1 | N3 alkylated benzimidazole derivatives as MEK inhibitors | CCNI, BRAF, CDK2 | MAP2K1 106/4885MAP2K2 108/4885SMC2 2986/4885 |
| US-10646567-B2 | Methods of treating cancer using PD-1 axis binding antagonists and MEK inhibitors | CD274, PDCD1, PDCD1LG2 | MAP2K1 13/4885MAP2K2 17/4885SMC2 4284/4885 |
| US-20050143438-A1 | N3 alkylated benzimidazole derivatives as MEk inhibitors | BRAF, CCNI, NRAS | MAP2K1 164/4885MAP2K2 155/4885SMC2 3447/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.